Navigation Links
Acetadote(R) Approved in Australia for Treatment of Acetaminophen Poisoning
Date:5/11/2010

NASHVILLE, Tenn., May 11 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. ( CPIX) and Phebra Pty Ltd. today announced that Acetadote® (acetylcysteine) Injection has been granted regulatory approval for marketing and sale in Australia. Acetadote, an injectable drug used to treat acetaminophen (paracetamol) overdose, was approved by the Therapeutic Goods Administration (TGA), the government agency responsible for regulating drugs and medical devices in Australia.

U.S.-based Cumberland Pharmaceuticals has granted an exclusive license to Phebra Pty Ltd., an Australian-based specialty pharmaceutical company, for commercialization of Acetadote in Australia. Phebra is now preparing for the Australian launch of the product, which it expects to commence in the coming weeks.

"We are delighted to obtain TGA approval for Acetadote and to make this product available to Australian hospitals," said Dr. Mal Eutick, President and Chief Executive Officer of Phebra. "We believe that using Acetadote to treat paracetamol poisoning offers a significant clinical benefit for patients and their caregivers in comparison to alternative courses of treatment, and look forward to communicating the product's benefits to the Australian medical community."

Acetadote is used in hospital emergency departments to prevent or lessen potential liver damage resulting from an overdose of acetaminophen, a common ingredient in many over-the-counter pain relief and fever reducing products. Since Cumberland Pharmaceuticals' U.S. introduction of the product in 2004, Acetadote has become a standard of care for treating acetaminophen poisoning.


'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cumberland Pharmaceuticals Provides Hospital In-Service Webcast for Acetadote(R)
2. ASP Sterrad Technology Approved by AFSSAPS for Total Inactivation of Prions
3. China YCT International Group, Inc. Announces That the State Intellectual Property Office of the Peoples Republic of China has Approved a Patent to its Operating Subsidiary, Shandong Spring Pharmaceutical Co. Ltd.
4. YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT
5. BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes
6. Recently Approved Onglyza Is Covered by 44 Percent of Commercial Health Plans But Less Than One Percent of Medicare Plans for The Treatment of Type 2 Diabetes
7. Accredited Construct Specific PCR Test for Recently Detected Unapproved GM Flax/Linseed FP967/CDC Triffid Available Through Genetic ID
8. YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO
9. American Scientific Resources To Be Exclusive Seller of Worlds Only FDA Approved Home Needle Destruction Device
10. Sumavel(TM) DosePro(TM) (sumatriptan injection) Approved by FDA for Acute Migraine and Cluster Headache: First Product Featuring Novel DosePro Needle-Free Delivery System
11. REMERON(R) Now Approved in Japan for the Treatment of Depression in Adult Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... -- The UPMC Center for Health Security today announced ... Leaders in Biosecurity Initiative (ELBI). As part of our ... biosecurity, UPMC has selected 28 US and international emerging ... including biological science, medicine, policy, the military, think tanks ... vision and support of the Defense Threat Reduction Agency ...
(Date:3/4/2015)... 4, 2015 /CNW/ - Resverlogix Corp. (TSX:RVX) (the ... a collaborative research program with Emerald Logic, ... Collective Evolution Technology (FACET), Emerald Logic analyzed ... obtained from each of 798 patients who ... trials ASSERT, SUSTAIN and ASSURE. The objective ...
(Date:3/4/2015)... SEOUL, South Korea , March 4, 2015 /PRNewswire/ ... based biopesticide company, in August of last year. As ... with Kyung Bon Koo continuing his role ... Selakovic , President of Vegalab S.A., will work alongside ... Photo - http://photos.prnewswire.com/prnh/20150303/179218 ...
(Date:3/3/2015)... 3, 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, ... molecular diagnostics that target the underlying mechanisms of cancer, ... period ended December 31, 2014. Effective July ... from May 31 to December 31. As a result ... are for the quarter and the seven months ended ...
Breaking Biology Technology:UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12
... and TORONTO, Jan. 25, 2012  Generex Biotechnology Corporation (OTCBB: GNBT) ... aggregate capital raise of CA$3,600,000.  This funding is structured as ... the Company,s real estate.  Interest on the loans is payable ... "This capital infusion will permit the Company to ...
... SAUSALITO, Calif., Jan. 24, 2012   Sanovas CEO Larry ... Times" as part of BayBio,s Life Sciences Series on Thursday, ... will take place at the Silicon Valley offices of DLA ... to funding and the emerging trends and opportunities in business ...
... 24, 2012  Forty-five percent of doctors in small or ... this year compared to last according to a survey ... Medical Record (EMR) company. The second annual State ... technology has made things easier for over 60 percent ...
Cached Biology Technology:Generex Secures Commitments for $3.6M Capital Raise 2Generex Secures Commitments for $3.6M Capital Raise 3Sanovas CEO Larry Gerrans Featured at BayBio's 'Fundraising in Troubled Times' 2Survey: Small Medical Practice Confidence Index Rises in 2012 2Survey: Small Medical Practice Confidence Index Rises in 2012 3Survey: Small Medical Practice Confidence Index Rises in 2012 4
(Date:2/25/2015)... , Feb. 25, 2015  ABC Financial ... billing in the Health and Fitness Industry, today ... as to MYiCLUBonline.  The latest upgrade includes advances ... inclusion of cardless check-in via Identity One fingerprint ... first time through interactive displays at the International ...
(Date:2/23/2015)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announced ... DISTRIBUTED VOICE DIRECTED PAYMENT METHOD AND SYSTEM. ... groundbreaking payment method. Payment accounts may be selected via ... accessed if both the speech (the word associated with ...
(Date:2/12/2015)... Minn. , Feb. 12, 2015   ... company specializing in clinical study management systems, has ... Program , further distinguishing iMedNet ... Clinical Research Organizations (CROs) and healthcare consultants.  Building ... support, prospective customer referrals and numerous co-marketing opportunities), ...
Breaking Biology News(10 mins):ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2
... 2014 Research ... addition of the  "Global Bioinformatics Market 2013 ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... the various sectors covered in this report ...
... a way to measure the mass of particles with ... of a trillionth of a gram. Weighing these tiny ... cells, could help researchers better understand their composition and ... developed by Scott Manalis, an MIT professor of biological ...
... The American Society for Microbiology (ASM) announces a new ... of science, policy, and the global challenges we all ... Each issue will feature articles and interviews ... explores the question, "What is the role of scientists ...
Cached Biology News:Global Bioinformatics Market 2013 - 2017 2Global Bioinformatics Market 2013 - 2017 3Weighing particles at the attogram scale 2Weighing particles at the attogram scale 3Weighing particles at the attogram scale 4
... Adept CE 4100 high pressure pump ... precision, with software drive compensation, reducing pulsing ... are selectable in 0.001mL steps. , The ... and bio-compatible., Pumps may be programmed from ...
High affinity antibodies recognizes HSP70 protein from human cardiac tissue. Could be used for Westerb blotting application, ELISA....
Recommended for use as a cell culture substratum at 0.1-0.2 mg/cm 2 or 5-10 μl/cm 2 . Optimal concentration depends on cell type as well as the application or research objectives. Type B...
Monoclonal antibodies conjugated with rhodamine...
Biology Products: